All Stories

  1. Systematic Lymphatic Repair for Reduction of Postoperative Lymphatic Leak Following Neuroblastoma Resection

    Article • Journal of Pediatric Surgery, February 2024, Elsevier

    Dr Amos Loh

  2. BRD4 isoforms have distinct roles in tumour progression and metastasis in rhabdomyosarcoma

    Article • EMBO Reports, January 2024, Springer Science + Business Media

    Dr Amos Loh

  3. Data from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  4. Data from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  5. FIGURE 1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  6. FIGURE 1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  7. FIGURE 2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  8. FIGURE 2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  9. FIGURE 3 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  10. FIGURE 3 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  11. FIGURE 4 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  12. FIGURE 4 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  13. FIGURE 5 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  14. FIGURE 5 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  15. Figure S1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  16. Figure S1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  17. Figure S2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  18. Figure S2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  19. Figure S3 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  20. Figure S3 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  21. Figure S4 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  22. Figure S4 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  23. Figure S5 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  24. Figure S5 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  25. Figure S6 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  26. Figure S6 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  27. Figure S7 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  28. Figure S7 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  29. Supplementary Data - raw Western blot images from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  30. Supplementary Data - raw Western blot images from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  31. Supplementary Data 1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  32. Supplementary Data 1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  33. Supplementary Data 2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  34. Supplementary Data 2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  35. Supplementary Data 3 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  36. Supplementary Data 3 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  37. Supplementary Methods from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  38. Supplementary Methods from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  39. Table S1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  40. Table S1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  41. Table S2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  42. Table S2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  43. Targeted degradation of XIAP is sufficient and specific to induce apoptosis in MYCN-overexpressing high-risk neuroblastoma

    Article • Cancer Research Communications, October 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  44. Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody

    Article • Molecular Therapy — Oncolytics, September 2023, Elsevier

    Dr Amos Loh

  45. Solitary pulmonary nodule in an early adolescent

    Article • BMJ Case Reports, September 2023, BMJ

    Dr Amos Loh

  46. #299 Alveolar soft part sarcoma of the cervix mimicking a cervical fibroid: a diagnostic and management challenge

    Article • September 2023, BMJ

    Dr Amos Loh

  47. BRD4 isoforms have distinct roles in tumor progression and metastasis in embryonal rhabdomyosarcoma

    Article • July 2023, Cold Spring Harbor Laboratory Press

    Dr Amos Loh

  48. Aggressive Pursuit of No Evidence of Disease Status in Hepatoblastoma Improves Survival: An Observational Study

    Article • Journal of Pediatric Surgery, June 2023, Elsevier

    Dr Amos Loh

  49. Targeting RNA Polymerase I Transcription Activity in Osteosarcoma: Pre-Clinical Molecular and Animal Treatment Studies

    Article • Biomedicines, April 2023, MDPI AG

    Dr Amos Loh

  50. Implementation of Multidisciplinary Teams for the Treatment of Childhood Cancer

    Article • January 2023, Springer Science + Business Media

    Dr Amos Loh

  51. Mitochondrial calcium uptake regulates tumour progression in embryonal rhabdomyosarcoma

    Article • Cell Death and Disease, April 2022, Springer Science + Business Media

    Dr Amos Loh

  52. Impact of treatment refusal and abandonment on survival outcomes in pediatric osteosarcoma in Southeast Asia: A multicenter study

    Article • Pediatric Blood & Cancer, January 2022, Wiley

    Dr Amos Loh

  53. Postoperative Rather Than Preoperative Neutropenia Is Associated With Early Catheter-related Bloodstream Infections in Newly Diagnosed Pediatric Cancer Patients

    Article • The Pediatric Infectious Disease Journal, January 2022, Wolters Kluwer Health

    Dr Amos Loh

  54. Subcutaneous panniculitis‐like T‐cell lymphomas with homozygous inheritance of HAVCR2 mutations in Vietnamese pedigrees

    Article • Pediatric Blood & Cancer, August 2021, Wiley

    Dr Amos Loh

  55. Gastrointestinal and oncologic outcomes of pediatric gastrointestinal lymphoma following upfront resection or biopsy of bowel masses

    Article • Pediatric Surgery International, May 2021, Springer Science + Business Media

    Dr Amos Loh

  56. Rhabdomyosarcoma

    Article • January 2021, Springer Science + Business Media

    Dr Amos Loh

  57. Pediatric Solid Tumor Care and Multidisciplinary Tumor Boards in Low- and Middle-Income Countries in Southeast Asia

    Article • JCO Global Oncology, September 2020, American Society of Clinical Oncology (ASCO)

    Dr Amos Loh

  58. Neuroblastoma patient‐derived cultures are enriched for a mesenchymal gene signature and reflect individual drug response

    Article • Cancer Science, August 2020, Wiley

    Dr Amos Loh

  59. Massively parallel single-molecule telomere length measurement with digital real-time PCR

    Article • Science Advances, August 2020, American Association for the Advancement of Science

    Dr Amos Loh

  60. Larotrectinib followed by selitrectinib in a novel DCTN1–NTRK1 fusion undifferentiated pleomorphic sarcoma

    Article • Journal of Oncology Pharmacy Practice, July 2020, SAGE Publications

    Dr Amos Loh

  61. Rhabdomyosarcoma

    Article • January 2020, Springer Science + Business Media

    Dr Amos Loh

  62. Posterior retroperitoneoscopic adrenalectomy for pediatric adrenal tumors

    Article • Journal of Pediatric Surgery, November 2019, Elsevier

    Dr Amos Loh

  63. Destined to Die: Apoptosis and Pediatric Cancers

    Article • Cancers, October 2019, MDPI AG

    Dr Amos Loh

  64. Retroperitoneal tumors and congenital variations in vascular anatomy of retroperitoneal great vessels

    Article • Journal of Pediatric Surgery, October 2019, Elsevier

    Dr Amos Loh

  65. Evaluation of a Novel Bony Landmark-Based Method for Teaching Percutaneous Insertion of Subclavian Venous Catheters in Pediatric Patients

    Article • World Journal of Surgery, April 2019, Springer Science + Business Media

    Dr Amos Loh

  66. Primary Adrenal Angiomatoid Fibrous Histiocytoma With Novel EWSR1-ATF1 Gene Fusion Exon–Exon Breakpoint

    Article • Pediatric and Developmental Pathology, March 2019, SAGE Publications

    Dr Amos Loh

  67. Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations

    Article • Cancer Letters, February 2019, Elsevier

    Dr Amos Loh

  68. Soft Tissue Sarcomas

    Article • January 2019, Springer Science + Business Media

    Dr Amos Loh

  69. Clinical, pathological and loss of heterozygosity differences in Wilms tumors between Asian and non-Asian children

    Article • International Journal of Cancer, December 2018, Wiley

    Dr Amos Loh

  70. Clinical relevance of screening checklists for detecting cancer predisposition syndromes in Asian childhood tumours

    Article • npj Genomic Medicine, November 2018, Springer Science + Business Media

    Dr Amos Loh

  71. Clear cell sarcomas of the kidney are characterised by BCOR gene abnormalities, including exon 15 internal tandem duplications and BCOR-CCNB3 gene fusion

    Article • Histopathology, October 2017, Wiley

    Dr Amos Loh

  72. Clinical management of pheochromocytoma and paraganglioma in Singapore: missed opportunities for genetic testing

    Article • Molecular Genetics & Genomic Medicine, July 2017, Wiley

    Dr Amos Loh

  73. Operative and Immediate Postoperative Differences Between Traditional Multiport and Reduced Port Laparoscopic Total Splenectomy in Pediatric Patients

    Article • Journal of Laparoendoscopic & Advanced Surgical Techniques, February 2017, Mary Ann Liebert Inc

    Dr Amos Loh

  74. Management of a Kaposiform haemangioendothelioma of the kidney with Kasabach-Meritt phenomenon without chemotherapy

    Article • Pediatric Hematology Oncology Journal, October 2016, Elsevier

    Dr Amos Loh

  75. Re: External validation of the Paediatric Risk of Malignancy Index

    Article • BJOG An International Journal of Obstetrics & Gynaecology, June 2016, Wiley

    Dr Amos Loh

  76. Initial diagnostic management of pediatric bone tumors

    Article • Journal of Pediatric Surgery, June 2016, Elsevier

    Dr Amos Loh

  77. XAF1 promotes neuroblastoma tumor suppression and is required for KIF1Bβ-mediated apoptosis

    Article • Oncotarget, April 2016, Impact Journals, LLC

    Dr Amos Loh

  78. Thyroglossal duct cyst carcinoma: diagnostic and management considerations in a 15-year-old with a large submental mass

    Article • BMJ Case Reports, July 2015, BMJ

    Dr Amos Loh

  79. Novel Karyotypes and Cyclin D1 Immunoreactivity in Clear Cell Sarcoma of the Kidney

    Article • Pediatric and Developmental Pathology, July 2015, SAGE Publications

    Dr Amos Loh

  80. Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma

    Article • Clinical Cancer Research, April 2015, American Association for Cancer Research (AACR)

    Dr Amos Loh

  81. Long-term physiologic and oncologic outcomes of inferior vena cava thrombosis in pediatric malignant abdominal tumors

    Article • Journal of Pediatric Surgery, April 2015, Elsevier

    Dr Amos Loh

  82. Safety and diagnostic accuracy of tumor biopsies in children with cancer

    Article • Cancer, December 2014, Wiley

    Dr Amos Loh

  83. An Approach to Renal Masses in Pediatrics

    Article • PEDIATRICS, December 2014, American Academy of Pediatrics (AAP)

    Dr Amos Loh

  84. Influence of bony resection margins and surgicopathological factors on outcomes in limb-sparing surgery for extremity osteosarcoma

    Article • Pediatric Blood & Cancer, November 2014, Wiley

    Dr Amos Loh

  85. Targeting the DNA Repair Pathway in Ewing Sarcoma

    Article • Cell Reports, November 2014, Elsevier

    Dr Claudia A Benavente, Dr Amos Loh

  86. The Role of Thoracoscopic Surgery in Pediatric Oncology

    Article • Journal of Laparoendoscopic & Advanced Surgical Techniques, November 2014, Mary Ann Liebert Inc

    Dr Amos Loh

  87. Minimally invasive surgery in the management of abdominal tumors in children

    Article • Journal of Pediatric Surgery, July 2014, Elsevier

    Dr Amos Loh

  88. Management of Local Recurrence of Pediatric Osteosarcoma Following Limb-Sparing Surgery

    Article • Annals of Surgical Oncology, February 2014, Springer Science + Business Media

    Dr Amos Loh

  89. Diagnostic accuracy of preoperative alpha-fetoprotein as an ovarian tumor marker in children and adolescents: not as good as we thought?

    Article • Pediatric Surgery International, May 2013, Springer Science + Business Media

    Dr Amos Loh

  90. Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration

    Article • Frontiers in Oncology, January 2013, Frontiers

    Dr Amos Loh

  91. Pediatric risk of malignancy index for preoperative evaluation of childhood ovarian tumors

    Article • Pediatric Surgery International, December 2011, Springer Science + Business Media

    Dr Amos Loh

  92. Diagnostic delay in pediatric solid tumors: A population based study on determinants and impact on outcomes

    Article • Pediatric Blood & Cancer, November 2011, Wiley

    Dr Amos Loh

  93. Corrigenda

    Article • Pediatric Hematology and Oncology, August 2011, Taylor & Francis

    Dr Amos Loh

  94. Gene Expression of TRK Neurotrophin Receptors in Advanced Neuroblastomas in Singapore—A Pilot Study

    Article • Pediatric Hematology and Oncology, July 2011, Taylor & Francis

    Dr Amos Loh

  95. Neonatal Ovarian Cysts: Role of Sonography in Diagnosing Torsion

    Article • Annals of the Academy of Medicine Singapore, June 2011, Academy of Medicine, Singapore

    Dr Amos Loh

  96. Delays in Diagnosis of Pediatric Solid Tumors in Singapore

    Article • Journal of Pediatric Hematology/Oncology, October 2009, Wolters Kluwer Health

    Dr Amos Loh

  97. Port-A-Cath insertions in acute leukemia: does thrombocytopenia affect morbidity?

    Article • Journal of Pediatric Surgery, July 2007, Elsevier

    Dr Amos Loh

  98. Port-A-Cath Insertions in Acute Leukaemia and Childhood Malignancies

    Article • Asian Journal of Surgery, July 2007, Elsevier

    Dr Amos Loh

  99. Neonatal intestinal volvulus due to a persistent right vitelline artery

    Article • Pediatric Surgery International, October 2006, Springer Science + Business Media

    Dr Amos Loh